Literature DB >> 21417908

Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer.

Frank A Sinicrope1, Zhineng Jayson Yang.   

Abstract

Colorectal cancers develop via two major pathways that include chromosomal instability and microsatellite instability. Microsatellite instability occurs due to deficient DNA mismatch repair (MMR), which can be caused by epigenetic silencing of the MLH1 MMR gene in sporadic colorectal cancers or germline mutations in MMR genes that result in Lynch syndrome. While the molecular origin of deficient MMR differs, sporadic and Lynch syndrome tumors share similar pathological features and have a more favorable stage-adjusted prognosis compared with MMR-proficient cases. While controversy remains, there is evidence to suggest that deficient MMR may predict a lack of benefit from 5-fluorouracil-based adjuvant chemotherapy. The focus of this article is on the MMR phenotype and its prognostic and predictive implications for the management of patients with colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417908      PMCID: PMC3770934          DOI: 10.2217/fon.11.5

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  62 in total

Review 1.  Cellular and molecular pharmacology of oxaliplatin.

Authors:  Eric Raymond; Sandrine Faivre; Stephen Chaney; Jan Woynarowski; Esteban Cvitkovic
Journal:  Mol Cancer Ther       Date:  2002-01       Impact factor: 6.261

2.  Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage.

Authors:  P Branch; G Aquilina; M Bignami; P Karran
Journal:  Nature       Date:  1993-04-15       Impact factor: 49.962

3.  An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair.

Authors:  A Kat; W G Thilly; W H Fang; M J Longley; G M Li; P Modrich
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

4.  CpG island methylator phenotype in colorectal cancer.

Authors:  M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Prediction of germline mutations and cancer risk in the Lynch syndrome.

Authors:  Sining Chen; Wenyi Wang; Shing Lee; Khedoudja Nafa; Johanna Lee; Kathy Romans; Patrice Watson; Stephen B Gruber; David Euhus; Kenneth W Kinzler; Jeremy Jass; Steven Gallinger; Noralane M Lindor; Graham Casey; Nathan Ellis; Francis M Giardiello; Kenneth Offit; Giovanni Parmigiani
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

6.  Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.

Authors:  Michael J O'Brien; Shi Yang; Charline Mack; Huihong Xu; Christopher S Huang; Elizabeth Mulcahy; Mark Amorosino; Francis A Farraye
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

7.  Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.

Authors:  A Zaanan; P Cuilliere-Dartigues; A Guilloux; Y Parc; C Louvet; A de Gramont; E Tiret; S Dumont; B Gayet; P Validire; J-F Fléjou; A Duval; F Praz
Journal:  Ann Oncol       Date:  2009-10-15       Impact factor: 32.976

Review 8.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Authors:  Gaëtan Des Guetz; Olivier Schischmanoff; Patrick Nicolas; Gérard-Yves Perret; Jean-François Morere; Bernard Uzzan
Journal:  Eur J Cancer       Date:  2009-05-06       Impact factor: 9.162

Review 9.  Genomic and epigenetic instability in colorectal cancer pathogenesis.

Authors:  William M Grady; John M Carethers
Journal:  Gastroenterology       Date:  2008-09-04       Impact factor: 22.682

10.  Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Authors:  W Chua; D Goldstein; C K Lee; H Dhillon; M Michael; P Mitchell; S J Clarke; B Iacopetta
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

View more
  7 in total

Review 1.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 2.  Big Bang Tumor Growth and Clonal Evolution.

Authors:  Ruping Sun; Zheng Hu; Christina Curtis
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 3.  A population genetics perspective on the determinants of intra-tumor heterogeneity.

Authors:  Zheng Hu; Ruping Sun; Christina Curtis
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-06       Impact factor: 10.680

4.  Predictive markers for the response to 5-fluorouracil therapy in cancer cells: Constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy.

Authors:  E M Saleh; R A El-Awady; N Anis
Journal:  Oncol Lett       Date:  2012-10-11       Impact factor: 2.967

5.  Microsatellite Instability assessment in Black South African Colorectal Cancer patients reveal an increased incidence of suspected Lynch syndrome.

Authors:  M McCabe; Y Perner; R Magobo; P Magangane; S Mirza; C Penny
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

6.  High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer.

Authors:  Amr Mohamed; Renjian Jiang; Philip A Philip; Maria Diab; Madhusmita Behera; Christina Wu; Olatunji Alese; Walid L Shaib; Tyra M Gaines; Glen G Balch; Bassel F El-Rayes; Mehmet Akce
Journal:  Front Oncol       Date:  2021-10-25       Impact factor: 6.244

7.  Mismatch repair-deficient status associates with favorable prognosis of Eastern Chinese population with sporadic colorectal cancer.

Authors:  Qing Gong; Huan-Hu Zhang; Sheng-Bo Sun; Wen-Min Ge; Yue Li; Yong-Cun Zhu; Le-Ping Li
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.